tetano
Editor, Senior Moderator
Vaccine
. 2024 May 27:S0264-410X(24)00602-9.
doi: 10.1016/j.vaccine.2024.05.043. Online ahead of print. Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review
Kavita Renduchintala[SUP] 1 [/SUP], Mariana Arevalo[SUP] 2 [/SUP], Gabriella Fonseca[SUP] 3 [/SUP], Mary Katherine Haver[SUP] 4 [/SUP], Clement K Gwede[SUP] 5 [/SUP], Smitha Pabbathi[SUP] 6 [/SUP], Shannon M Christy[SUP] 7 [/SUP]
Affiliations
Background: Our goal was to provide an overview of uptake rates across vaccine types and factors associated with vaccine uptake among cancer survivor populations.
Methods: A literature search was conducted using Ovid MEDLINE® ALL (Wolters Kluwer), Embase (Elsevier) and CINAHL Complete (EBSCO) databases and according to PRISMA guidelines. Eligible articles were limited to those examining vaccination uptake among cancer survivors who had completed treatment, reported factors associated with uptake (e.g., barriers and facilitators), and published in English between 2011 and 2021. Two independent reviewers screened citations for inclusion and two performed data abstraction, verified by an arbiter.
Results: The search returned 4,215 total articles, and 271 duplicates were removed. During abstract/title screening, 212 articles were identified. Following full-text screening, 47 articles/abstracts were found to meet inclusion criteria, 16 articles/abstracts were removed, and 31 studies were included in the review. Among the 31 studies, participant age ranged from 9 years to adults of all ages. Vaccine types included: influenza (n = 18), human papillomavirus (n = 10), pneumococcal (n = 8), hepatitis A/B (n = 1), shingles (n = 1), measles (n = 1), tetanus/diphtheria (n = 1), and haemophilus influenza B (n = 1). Vaccine uptake varied greatly across studies, vaccine types, and participant populations. Factors affecting vaccination uptake included sociodemographic variables and social determinants of health, health beliefs/attitudes/knowledge, provider recommendation, and cancer treatment/clinical variables.
Conclusions: Our findings highlight the need for further examining factors associated with vaccine uptake, the need for clinical guidelines that specifically address vaccination among cancer survivors, and potential targets for multi-level interventions to improve vaccination rates among cancer survivor populations.
. 2024 May 27:S0264-410X(24)00602-9.
doi: 10.1016/j.vaccine.2024.05.043. Online ahead of print. Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review
Kavita Renduchintala[SUP] 1 [/SUP], Mariana Arevalo[SUP] 2 [/SUP], Gabriella Fonseca[SUP] 3 [/SUP], Mary Katherine Haver[SUP] 4 [/SUP], Clement K Gwede[SUP] 5 [/SUP], Smitha Pabbathi[SUP] 6 [/SUP], Shannon M Christy[SUP] 7 [/SUP]
Affiliations
- PMID: 38802291
- DOI: 10.1016/j.vaccine.2024.05.043
Background: Our goal was to provide an overview of uptake rates across vaccine types and factors associated with vaccine uptake among cancer survivor populations.
Methods: A literature search was conducted using Ovid MEDLINE® ALL (Wolters Kluwer), Embase (Elsevier) and CINAHL Complete (EBSCO) databases and according to PRISMA guidelines. Eligible articles were limited to those examining vaccination uptake among cancer survivors who had completed treatment, reported factors associated with uptake (e.g., barriers and facilitators), and published in English between 2011 and 2021. Two independent reviewers screened citations for inclusion and two performed data abstraction, verified by an arbiter.
Results: The search returned 4,215 total articles, and 271 duplicates were removed. During abstract/title screening, 212 articles were identified. Following full-text screening, 47 articles/abstracts were found to meet inclusion criteria, 16 articles/abstracts were removed, and 31 studies were included in the review. Among the 31 studies, participant age ranged from 9 years to adults of all ages. Vaccine types included: influenza (n = 18), human papillomavirus (n = 10), pneumococcal (n = 8), hepatitis A/B (n = 1), shingles (n = 1), measles (n = 1), tetanus/diphtheria (n = 1), and haemophilus influenza B (n = 1). Vaccine uptake varied greatly across studies, vaccine types, and participant populations. Factors affecting vaccination uptake included sociodemographic variables and social determinants of health, health beliefs/attitudes/knowledge, provider recommendation, and cancer treatment/clinical variables.
Conclusions: Our findings highlight the need for further examining factors associated with vaccine uptake, the need for clinical guidelines that specifically address vaccination among cancer survivors, and potential targets for multi-level interventions to improve vaccination rates among cancer survivor populations.